- Raised $6.6M funding round, Oct 2021
- Raised $155k funding round, Apr 2025
- Raised $1M funding round, Mar 2025
About
Innocan Pharma is a pharmaceutical technology company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprised of cannabinoids science to treat various conditions and improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform, which facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; and (ii) CLX CBD-loaded exosomes platform, which aims to target the central nervous system through regeneration and by addressing inflammation.
In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd., which focuses on developing advanced targeted online sales.
Funding history · 10 rounds · $23.7M total
Q&A
- What is InnoCan Pharma's primary focus?
- InnoCan Pharma is a pharmaceutical technology company focused on developing cannabinoid-integrated pharmaceutical products, operating in both Pharmaceuticals and Consumer Wellness segments.
- When was InnoCan Pharma founded?
- InnoCan Pharma was founded in October 2017.
- What is InnoCan Pharma's employee count?
- InnoCan Pharma has 11-50 employees.
- What is the total amount of funding InnoCan Pharma has raised to date?
- InnoCan Pharma has raised a total of $23,669,000 USD.
- When was InnoCan Pharma's most recent funding round and how much was raised?
- InnoCan Pharma's most recent funding round was in April 2025, raising $155,000 USD.
- Which investors participated in InnoCan Pharma's March 2025 funding round?
- InnoCan Pharma's March 2025 funding round included Tamar Innovest.
- What is InnoCan Pharma's current market capitalization?
- InnoCan Pharma's market capitalization is $51,200,560 USD.
- What are the two main drug delivery platform technologies InnoCan Pharma is developing?
- InnoCan Pharma is developing two drug delivery platform technologies: LPT CBD-loaded liposome platform and CLX CBD-loaded exosomes platform.
- When did InnoCan Pharma become publicly traded?
- InnoCan Pharma became public on the CSE in September 2019 and on OTCQB in August 2021.
Team · 4
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | innocanpharma.com |
|---|---|
| linkedin.com/company/28636009 | |
| facebook.com/Innocanpharma | |
| YouTube | youtube.com/channel/UCPRlEVlWy3JkCfNIn17GLxw |
Identifiers & details
| Former names | CANNAHEALTH PHARMACEUTICALS |
|---|---|
| Founded | 2017-10 |
| Employees (exact) | 15 |
| Market cap | $51.2M |
| Status reason | Public on CSE on Sep, 2019;Public on OTCQB on Aug, 2021; |
Radar intelligence
Patents
| EPO | 10 |
|---|
Web history (Wayback)
| Domain | innocanpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|